Your browser doesn't support javascript.
loading
Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling.
van der Leest, Paul; Ketelaar, Emma M; van Noesel, Carel J M; van den Broek, Daan; van Boerdonk, Robert A A; Deiman, Birgit; Rifaela, Naomi; van der Geize, Robert; Huijsmans, Cornelis J J; Speel, Ernst Jan M; Geerlings, Maartje J; van Schaik, Ron H N; Jansen, Maurice P H M; Dane-Vogelaar, Ria; Driehuis, Else; Leers, Mathie P G; Sidorenkov, Grigory; Tamminga, Menno; van Kempen, Léon C; Schuuring, Ed.
Afiliación
  • van der Leest P; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Ketelaar EM; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • van Noesel CJM; Department of Pathology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands.
  • van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Boerdonk RAA; Department of Pathology, Amsterdam University Medical Centres, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Deiman B; Clinical Laboratory, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
  • Rifaela N; Institute for Complex Molecular Systems, Laboratory of Chemical Biology, Eindhoven University of Technology, Eindhoven, The Netherlands.
  • van der Geize R; Department of Biomedical Engineering, Laboratory of Chemical Biology, Eindhoven University of Technology, Eindhoven, The Netherlands.
  • Huijsmans CJJ; Expert Center Clinical Chemistry Eindhoven, Eindhoven, The Netherlands.
  • Speel EJM; Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Geerlings MJ; Department of Molecular Pathology, Laboratorium Pathologie Oost-Nederland, Hengelo, The Netherlands.
  • van Schaik RHN; Pathologie-DNA, Laboratory for Molecular Diagnostics, location Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
  • Jansen MPHM; Department of Pathology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Dane-Vogelaar R; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Driehuis E; Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
  • Leers MPG; Department of Medical Oncology, Laboratory of Translational Genomics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
  • Sidorenkov G; Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Tamminga M; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van Kempen LC; Department of Clinical Chemistry & Hematology, Zuyderland Medical Center, Sittard-Geleen/Heerlen, The Netherlands.
  • Schuuring E; Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Clin Chem ; 68(7): 963-972, 2022 07 03.
Article en En | MEDLINE | ID: mdl-35616097
ABSTRACT

BACKGROUND:

Efficient recovery of circulating tumor DNA (ctDNA) depends on the quantity and quality of circulating cell-free DNA (ccfDNA). Here, we evaluated whether various ccfDNA extraction methods routinely applied in Dutch laboratories affect ccfDNA yield, ccfDNA integrity, and mutant ctDNA detection, using identical lung cancer patient-derived plasma samples.

METHODS:

Aliquots of 4 high-volume diagnostic leukapheresis plasma samples and one artificial reference plasma sample with predetermined tumor-derived mutations were distributed among 14 Dutch laboratories. Extractions of ccfDNA were performed according to local routine standard operating procedures and were analyzed at a central reference laboratory for mutant detection and assessment of ccfDNA quantity and integrity.

RESULTS:

Mutant molecule levels in extracted ccfDNA samples varied considerably between laboratories, but there was no indication of consistent above or below average performance. Compared to silica membrane-based methods, samples extracted with magnetic beads-based kits revealed an overall lower total ccfDNA yield (-29%; P < 0.0001) and recovered fewer mutant molecules (-41%; P < 0.01). The variant allelic frequency and sample integrity were similar. In samples with a higher-than-average total ccfDNA yield, an augmented recovery of mutant molecules was observed.

CONCLUSIONS:

In the Netherlands, we encountered diversity in preanalytical workflows with potential consequences on mutant ctDNA detection in clinical practice. Silica membrane-based methodologies resulted in the highest total ccfDNA yield and are therefore preferred to detect low copy numbers of relevant mutations. Harmonization of the extraction workflow for accurate quantification and sensitive detection is required to prevent introduction of technical divergence in the preanalytical phase and reduce interlaboratory discrepancies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Patología Clínica / Ácidos Nucleicos Libres de Células / ADN Tumoral Circulante / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Clin Chem Asunto de la revista: QUIMICA CLINICA Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Patología Clínica / Ácidos Nucleicos Libres de Células / ADN Tumoral Circulante / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Clin Chem Asunto de la revista: QUIMICA CLINICA Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos